Category: M&A / Deals

Pharmaceutical Technology

Daiichi Sankyo has partnered with Interna Therapeutics to develop targeted delivery solutions based on molecular nano motor (MNM) technology.

M&A / DealsRead full story

BioSpace

Commitments in obesity- and diabetes-focused deals reached $22 billion in the first quarter of 2026–already eclipsing last year’s total of $20.3 billion, according to a new J.P.

M&A / DealsMetabolic & GLP-1Read full story

Pharmaphorum

Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.

M&A / DealsRead full story

Pharmaceutical Technology

Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity.

M&A / DealsOncologyRead full story

BioPharma Dive

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.

M&A / DealsImmunology & InflammationRead full story

Pharmaceutical Technology

Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.

M&A / DealsRead full story

Pharmaceutical Business Review

The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer.

M&A / DealsRead full story

Pharmaceutical Technology

Adcendo, a clinical-stage biotechnology company developing ADCs for cancer treatment, has raised $75m in a Series C funding round.

M&A / DealsOncologyRead full story

Pharmaceutical Business Review

The financing will support Adcendo’s ongoing advancement of its first-in-class and best-in-class ADC pipeline targeting cancers of high unmet medical need, including further clinical development of th

M&A / DealsOncologyRead full story

BioSpace

After divorcing Denali Therapeutics earlier this month, Takeda is now splitting up with Veritas In Silico, pulling back from a partnership that advanced novel small-molecule drugs targeting mRNA.

M&A / DealsRead full story

Pharmaphorum

A new R D project will try to develop assays for LRRK2, a biomarker linked to Parkinson’s that has emerged as a major drug target in the disease.

M&A / DealsNeuroscienceRead full story

Pharmaphorum

Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.

M&A / DealsRead full story

BioSpace

Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data expected later this year.

M&A / DealsImmunology & InflammationRead full story

BioPharma Dive

Worth up to $300 million, the buyout is Lilly s latest of an ADC maker and adds technology for making dual-payload therapies.

M&A / DealsOncologyRead full story

Pharmaphorum

Seeking an R D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.

M&A / DealsRead full story

BioSpace

The licensing deal marks AbbVie’s first foray into new pain medicines, a space where Vertex currently enjoys a lead thanks to the NaV1.8 inhibitor Journavx.

M&A / DealsPain & AnaesthesiaRead full story

Pharmaceutical Technology

AbbVie’s deal with Haisco comes as many pharma companies look to restock their pipelines amid looming global patent expiries.

M&A / DealsPain & AnaesthesiaRead full story

BioPharma Dive

The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer.

M&A / DealsOncologyRead full story

Pharmaphorum

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

M&A / DealsOncologyRead full story

Pharmaceutical Technology

Roche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer.

M&A / DealsOncologyRead full story